戴维医疗 (300314.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

22.5x

Market Cap

CNY 3.59B

MomentumView details →

1D Return

−5.03%

YTD Return

−8.35%

RSI (14)

48.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

22.5x

Market Cap

CNY 3.59B

RSI (14)

48.2

MomentumView details →

1D Return

−5.03%

YTD Return

−8.35%

ProfitabilityView details →

Gross Margin

52.16%

Net Margin

12.92%

EBITDA Margin

21.78%

ROE (TTM)

5.99%

ROA (TTM)

5.13%

Asset Turnover

0.39x

GrowthView details →

Revenue YoY

+16.80%

EPS YoY

+78.08%

FCF YoY

+176.96%

Revenue CAGR 3Y

+4.89%

EPS CAGR 3Y

−4.09%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.48x

Quick Ratio

3.43x

Div Yield

0.69%

Div Rate

CNY 0.08

Div Growth 1Y

−8.05%

Financials snapshotView financials →

Revenue (TTM)

575.66M

Net Income (TTM)

74.37M

Op. CF (TTM)

84.03M

Latest newsMore news →

Daiwei Medical announced its first-half 2026 results: net profit attributable to shareholders fell 52.75% year-on-year to 24.088 million yuan, with revenue up 0.26% to 252 million yuan.16d ago

Similar companies

华塑科技301157.SZ 宝色股份300402.SZ 德尔玛301332.SZ ST云动000903.SZ 东箭科技300978.SZ 鼎汉技术300011.SZ Find similar companies →

Latest newsMore news →

Daiwei Medical announced its first-half 2026 results: net profit attributable to shareholders fell 52.75% year-on-year to 24.088 million yuan, with revenue up 0.26% to 252 million yuan.16d ago